Purpose: We aimed to investigate the efficacy and safety of zoledronic acid combined with chemotherapy in treating non-small cell lung cancer (NSCLC) with bone metastasis.
Methods: The clinical data of 148 NSCLC patients with bone metastasis were retrospectively analyzed. Among the patients, 74 were treated with zoledronic acid combined with chemotherapy (Zoledronic Acid group), while the remaining 74 received chemotherapy alone (Control group). The efficacy on bone metastasis, remission of bone pain, levels of bone metabolic markers before and after treatment, quality of life and incidence rate of adverse reactions were compared between the two groups. Besides, the patients were followed up, and their survival status was recorded.
Results: The efficacy was evaluated in all patients at 1 month after treatment. It was found that the overall response rate of bone metastasis was significantly higher in the Zoledronic Acid group than that in the Control group. After treatment, the ostealgia remission rate was markedly higher in the Zoledronic Acid group than that in the Control group. After treatment, the serum levels of alkaline phosphatase (AKP), Ca2+, N-terminal telopeptide (NTx) and bone sialoprotein (BSP) declined notably in both groups in contrast with those before treatment, and they were prominently lower in the Zoledronic Acid group than those in the Control group after treatment. Moreover, after treatment, the Karnofski performance status (KPS) score was improved in both groups, and the Zoledronic Acid group had an evidently higher score than the Control group. The results of follow-up manifested that the 1-, 2- and 3-year overall survival (OS) rates in the Zoledronic Acid group and the Control group were 58.1% (43/74) vs. 43.2% (32/74), 40.5% (30/74) vs. 29.7% (22/74), and 24.3% (18/74) vs. 13.5% (10/74), respectively. Log-rank test revealed that the OS in the Zoledronic Acid group was significantly better than that in the Control group.
Conclusion: Zoledronic acid combined with chemotherapy is effective in the treatment of NSCLC with bone metastasis, which can markedly relieve bone pain, ameliorate the quality of life of patients, improve the long-term survival rate and reduce the incidence of SREs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical features, treatment, and prognosis of zoledronic acid-induced uveitis.
Eye (Lond)
January 2025
College of pharmacy, Changsha Medical University, Changsha, China.
Background: Uveitis is a rare ocular adverse reaction of zoledronic acid, the specific clinical features are not clarified. This study was to investigate the clinical features of zoledronic acid-induced uveitis and provide reference for rational use of zoledronic acid.
Methods: We collected clinical data on zoledronic acid-induced uveitis for retrospective analysis by searching Chinese and English data up to October 31, 2024.
Administration of Bisphosphonate Preparations to Mice with Mild-type Hypophosphatasia Reduces the Quality of Spontaneous Locomotor Activity.
Calcif Tissue Int
January 2025
Department of Pharmacology, Tokyo Dental College, 2-9-18, Kandamisaki-cho, Chiyoda-ku, Tokyo, 101-0061, Japan.
Hypophosphatasia (HPP) is a congenital bone disease caused by tissue-nonspecific mutations in the alkaline phosphatase gene. It is classified into six types: severe perinatal, benign prenatal, infantile, pediatric, adult, and odonto. HPP with femoral hypoplasia on fetal ultrasonography, seizures, or early loss of primary teeth can be easily diagnosed.
View Article and Find Full Text PDFOsteoporosis Caused by Monoallelic Variant of WNT1 Gene in Four Pediatric Patients.
Am J Med Genet A
January 2025
Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Pediatric patients of autosomal dominant early onset osteoporosis conferred by heterozygous mutation in the WNT1 (OMIM: 615221) were rarely reported, and therapy in pediatrics is relatively inexperienced. The clinical and genotypic characteristics and treatment process of four children with osteoporosis caused by WNT1 monoallelic variation were analyzed. The patients admitted from June 2023 to January 2024.
View Article and Find Full Text PDFBisphosphonate-mineralized nano-IFNγ suppresses residual tumor growth caused by incomplete radiofrequency ablation through metabolically remodeling tumor-associated macrophages.
Theranostics
January 2025
Beijing Key Laboratory of Molecular Pharmaceutics and Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Radiofrequency ablation (RFA), as a minimally invasive surgery strategy based on local thermal-killing effect, is widely used in the clinical treatment of multiple solid tumors. Nevertheless, RFA cannot achieve the complete elimination of tumor lesions with larger burden or proximity to blood vessels. Incomplete RFA (iRFA) has even been validated to promote residual tumor growth due to the suppressive tumor immune microenvironment (TIME).
View Article and Find Full Text PDFComparative Analysis of Extracorporeal Shockwave Therapy, Bisphosphonate, and Wharton Jelly-Derived Mesenchymal Stem Cells in Preserving Bone and Cartilage Integrity and Modulating IL31, IL33, and BMP2 in the Cartilage of Ovariectomized Rat Model.
Biomedicines
December 2024
Department of Orthopedic Surgery, Sports Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
Osteoporosis (OP) is a chronic inflammatory bone disease characterized by reduced bone structure and strength, leading to increased fracture risk. Effective therapies targeting both bone and cartilage are limited. This study compared the therapeutic effects of extracorporeal shockwave therapy (ESWT), bisphosphonate (Aclasta), and human Wharton jelly-derived mesenchymal stem cells (WJMSCs) in a rat model of OP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!